Cardiovascular Pathology
Volume 19, Issue 2 , Pages 125-126 , March 2010

Blue dye, green heart

Received 3 April 2008 ,Revised 20 May 2008 ,Accepted 25 June 2008.

References 

  1. Preiser JC, Lejeune P, Roman A, et al. Methylene blue administration in septic shock: a clinical trial. Crit Care Med. 1995;23:259–264
  2. Levin RL, Degrange MA, Bruno GF, et al. Methylene blue reduces mortality and morbidity in vasoplegic patients after cardiac surgery. Ann Thorac Surg. 2004;77:496–499
  3. Shanmugam G. Vasoplegic syndrome—the role of methylene blue. Eur J Cardiothorac Surg. 2005;28:705–710
  4. Evora PR, Viaro F. The guanylyl cyclase inhibition by MB as vasoplegic circulatory shock therapeutical target. Curr Drug Targets. 2006;7:1195–1204
  5. Buchholz K, Schirmer RH, Eubel JK, et al. Interactions of methylene blue with human disulfide reductases and their orthologues from Plasmodium falciparum. Antimicrob Agents Chemother. 2008;52:183–191

PII: S1054-8807(08)00072-0

doi: 10.1016/j.carpath.2008.06.012

Cardiovascular Pathology
Volume 19, Issue 2 , Pages 125-126 , March 2010

Article Tools

* Image Usage & Resolution